Trial Profile
Study comparing standard dose and high-dose imatinib mesylate in patients with chronic phase Ph+ CML.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 30 Apr 2012 Planned end date (Jun 2007) added as reported by ClinicalTrials.gov.
- 23 Oct 2005 New trial record.